At LSBC, part of our mission is to encourage the next generation to pursue STEM careers, and Science Fair Foundation BC’s 2022 Youth Innovation Showcase is an exciting event that welcomes youth to share their innovations! There are many inspiring leaders for youth to look up to, including Helen Sheridan, STEMCELL Technologies’ Chief Human Resources Officer, who recently shared in a BC Tech Association Q&A, “our sector can lead the way in improving the living standards of all British Columbians”.
Speaking of awards, Bloom Burton & Co has announced the finalists for the 2022 Bloom Burton Award, which recognizes significant contributions to Canada’s healthcare industry: Frank Baylis, Executive Chairman, and Kris Shah, President, Baylis Medical Technologies; Jan Skvarka, former President and Chief Executive Officer, Trillium Therapeutics; and Pieter Cullis, Co-Founder and Chairman, Acuitas Therapeutics. Congratulations also to Aspect Biosystems CEO Tamer Mohamed for being named among the Top 50 Healthcare Technology CEOs of 2022 by The Healthcare Technology Report.
New investments continue to be made within the sector, such as the recent Canadian government announcement of $1 billion towards a new innovation agency to improve Canadian innovation in science and technology.
Next week is International Clinical Trials Day (May 20th) - a day that marks the first clinical trial. Raising awareness around clinical trials allows people to make informed decisions around participation, which can help advance prevention, diagnosis, and treatment. To this point, the Society for Clinical Trials has announced The TOGETHER Trial: An Adaptive Platform International Trial as the winner of its prestigious David Sackett Trial of the Year Award. This trial is the largest placebo-controlled clinical trial for the evaluation of COVID-19 therapeutics in the world, and has enrolled more than 5,000 patients in community-based settings, whose data have contributed to the evaluations of 11 different potentially life-saving therapeutic interventions. Congratulations to all who are involved!
In closing, it is awesome to see strong attendance at events within the sector. This week saw more than 550 attendees attend the EFFERVESCENCE Conference. Congratulations to Montreal InVivo on organizing the conference, and to Axolotl Biosciences for being selected for the pitch contest. Thank you also to those who attended our Surrey Showcase Series, which showcased a dynamic mix of partners who are building our sector south of the Fraser. With more than 105 registrants across 76 organizations in attendance, we couldn’t be more pleased to highlight the depth of talent, spirit of innovation and deep commitment to collaboration that makes our sector a global standout.
Wendy and the LSBC team
|
|
|
|
Upadacitinib (RINVOQ®) Achieved Clinical Remission and Endoscopic Response at One Year in Phase 3 Maintenance Study in Patients with Crohn’s Disease
AbbVie announced positive topline results from U-ENDURE, its Phase 3 maintenance study evaluating upadacitinib in adult patients with moderate to severe Crohn’s disease who had an inadequate response or were intolerant to a conventional or biologic therapy. The results showed that more patients treated with either dose of upadacitinib (15 mg or 30 mg once daily) achieved the co-primary endpoints of endoscopic response and clinical remission, as well as the secondary endpoint of endoscopic remission, at one year (week 52) compared to placebo... READ MORE
|
|
|
|
adMare BioInnovations Joins a $42m Series A Financing in Domain Therapeutics
Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors in immuno-oncology, announced the closing of a $42m (€39m) series A financing round co-led by Panacea Venture, CTI Life Sciences and 3B Future Health Fund, and joined by adMare BioInnovations, Schroder Adveq, Omnes Capital, Turenne Capital, Theodorus, Viva BioInnovator and existing investor Seventure Partners... READ MORE
|
|
|
|
Avantor® and Cytovance Biologics Collaborate to Accelerate Plasmid DNA Development for Biopharma Customers
Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, and Cytovance Biologics, Inc., a biologics contract development and manufacturing organization specializing in the manufacturing of high-quality plasmid DNA have entered into an agreement to manufacture research and GMP grade plasmids for biopharma customers... READ MORE
|
|
|
|
B.C. Researchers Launching Clinical Trial for First Genetically Engineered Stem Cell-Based Therapy for Type 1 Diabetes
Researchers from the University of British Columbia (UBC) and Vancouver Coastal Health have received $1 million from Canada’s Stem Cell Network to conduct research and a clinical trial for one of the world’s first genetically engineered cell replacement therapies for type 1 diabetes. The researchers say the study is an important step toward developing a potential functional cure for type 1 diabetes... READ MORE
|
|
|
|
Izotropic Unveils Izoview Commercial Prototype, Files New Patients
Izotropic Corporation, a company commercializing a dedicated breast CT (computed tomography) imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers, is pleased to unveil the commercial prototype device design that will be used in forthcoming clinical studies for market authorization in the U.S.... READ MORE
|
|
|
|
Willow Biosciences Announces Expansion of its Fermentation Manufacturing Network and Progress on its CBG Gras Determination
Willow Biosciences Inc., a leading biotechnology company focused on revolutionizing industrial manufacturing of high-value molecules traditionally derived from plants, announces expanded production capacity with a new manufacturing partnership and progress with respect to its Generally Recognized as Safe determination... READ MORE
|
|
|
|
Sanofi Biogenius Canada Competition Returns to Canada-Wide Science Fair
Sanofi Canada is proud to partner with Youth Science Canada (YSC) for the 30th annual Sanofi Biogenius Canada Competition, which will take place during the 60th edition of YSC’s Canada-Wide Science Fair from May 16 to 20. Originally launched in partnership with YSC, the inaugural Competition was held during 1992 in Sudbury, Ontario... READ MORE
|
|
|
|
Aspect Biosystems to Present on Liver and Pancreatic Tissue Therapeutics at American Society of Gene & Cell Therapy 25th Annual Meeting
Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat disease, will present on its liver and pancreas tissue therapeutic programs at the American Society of Gene & Cell Therapy 25th Annual Meeting, held May 16-19, 2022 in Washington, DC and virtually... READ MORE
|
|
|
|
Roche Pledges to Extend Commitment to the World Federation of Hemophilia Humanitarian Aid Program to 2028
Roche announced that it has extended its commitment to the World Federation of Hemophilia Humanitarian Aid Program until the end of 2028. Roche’s prophylactic treatment will be provided to the WFH Humanitarian Aid Program to continue to treat as many as 1,000 people with haemophilia A in locations where there is little to no access to treatment. The partnership, which was originally formed by Roche and the WFH in February 2019, marked the first time that patients in developing countries had received access to a prophylactic treatment. The donated treatment has since benefited more than 940 people across 30 countries... READ MORE
|
|
|
|
Northview Announces Investment into Total Flow Medical
Northview Lifesciences is pleased to announce that the 3.5M USD Seed financing for Total Flow Medical has closed oversubscribed at 4.1M USD. Northview will be participating in the Seed financing of Total Flow Medical as lead investor. This raise will advance their first product through to regulatory approval in preparation for commercialization. READ MORE
|
|
|
|
Bausch Health Announces Thomas J. Appio as Chief Executive Officer
Bausch Health Companies Inc. announced its full leadership team and Board of Directors, including Chief Executive Officer (CEO) Thomas J. Appio. Upon completion of the initial public offering (IPO) of the Bausch + Lomb eye health business, former CEO Joseph C. Papa will assume the role of chairman and CEO of Bausch + Lomb.“It is an honor and privilege to lead Bausch Health at this pivotal time in its history, and I am excited for our future,”... READ MORE
|
|
|
|
NervGen Pharma Receives Approval to Proceed to the Final Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q1 2022 Results
NervGen Pharma Corp., a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, today announced it has received approval from the Safety Review Committee to advance to the third and highest dose cohort in the multiple ascending dose portion of its Phase 1 clinical trial of the Company’s proprietary lead compound, NVG-291... READ MORE
|
|
|
|
Science Based Targets initiative (SBTi) Confirms Contribution of Merck KGaA, Darmstadt, Germany, to 1.5°C Climate Target
Merck KGaA, Darmstadt, Germany, a leading science and technology company, aims to significantly reduce its greenhouse gas emissions by 2030. The independent Science Based Targets initiative has confirmed that the company’s targets correspond to the current status of climate science. Consequently, Merck KGaA, Darmstadt, Germany, is helping to limit global warming to 1.5°C, thus meeting the requirements of the Paris Agreement... READ MORE
|
|
|
|
InMed to Supply Rare Cannabinoids to Radicle Science’s “Radicle Energy Study” to Assess the Health Effects of THCV
InMed Pharmaceuticals Inc., a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce that its subsidiary, BayMedica, will be providing rare cannabinoids for use in Radicle Science, Inc.’s Radicle Energy rare cannabinoid study to assess the effects of delta-9 (“d-9”) dominant tetrahydrocannabivarin (“THCV”) on energy, focus/attention, appetite and weight/BMI. BayMedia will be supplying its highly pure d-9 dominant THCV, formulated into a proprietary lozenge manufactured by Trokie... READ MORE
|
|
|
|
TOGETHER Trial Named David Sackett Trial of the Year 2021
The Society for Clinical Trials (SCT) is pleased to announce that the prestigious David Sackett Trial of the Year Award will be presented to The TOGETHER Trial: An Adaptive Platform International Trial. The award will be presented on May 16, 2022, as part of SCT’s 43rd Annual Meeting, “Informing Public Health Policy with Compelling Evidence,” May 15 – 18, 2022 at the Hilton San Diego Bayfront Hotel.. READ MORE
|
|
|
|
Zucara Therapeutics Secures Additional Funding from GlycoNet and Mitacs for the Development of ZT-01
Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), announced that it has received second grants from each of GlycoNet and Mitacs to support the development of ZT-01 for the treatment of insulin-induced hypoglycemia in people with Type 2 diabetes... READ MORE
|
|
|
|
Three Finalists Announced for the 2022 Bloom Burton Award
Bloom Burton & Co. announces the finalists for the 2022 Bloom Burton Award. Bestowed annually and nominated by the public at large, the Bloom Burton Award honours an individual who made the greatest contribution to Canada’s innovative healthcare industry in the previous year. ..READ MORE
|
|
|
|
Government of Canada Supports Research Focused on Race, Gender and Diversity
Community-based research is critical to better understanding the causes and persistence of systemic racism and to addressing disparities related to race, gender and other forms of diversity. That’s why the Government of Canada supports research focused on the lived experiences of people from underrepresented and disadvantaged groups. ..READ MORE
|
|
|
|
The 2022 Youth Innovation Showcase has Officially Launched
The 2022 Youth Innovation Showcase is looking for youth from across BC and the Yukon who are working on the next STEM breakthrough. Innovations big and small are invited to register for this year’s virtual competition by submitting a short pitch video explaining your innovation. Finalists will pitch their ideas live to industry experts in November for a chance to win $5,000. ..READ MORE
|
|
 |
HTuO Biosciences is on a mission: they want to make the process of designing drugs faster and more efficient, and to make it possible to target proteins that are currently outside the scope of traditional drug design - all while making it cheaper to bring those drugs to market. They believe that the best way to improve their understanding of molecular interactions is to create more accurate models, both of the molecules of interest as well as the solvent in which they're interacting.
|
|
|
|
PR Associates is a science-based public relations and communication agency that helps organizations pushing the boundaries of science to create solutions for some of the world’s most pressing problems get noticed. With our proven, 25-year track record of science storytelling, media relations and strategic communication, we help make your science be understood, establish credibility, and make meaningful connections with the people that matter most to you at the right time.
|
|
|
|
Biophysical Assays Scientist
Gandeeva Therapeutics is seeking a highly motivated Biophysical Assays Scientist to actively develop and implement assays to support Gandeeva drug discovery programs. Join them on their mission to bring new treatment options to patients by revolutionizing drug discovery!
|
|
Curriculum Developer and Instructor, Animal Cell Culture course
BCIT’s Department of Biotechnology is hiring for a curriculum development (140 hours, June 20th – July 15th) and instructor (55 hours, July 18th – July 29th) position. The successful candidate will be responsible for developing the laboratory and theoretical content for a new animal cell culture microcredential and will also implement and teach the laboratory course.
|
|
Senior/Principal Scientist, Pharmaceutical Sciences
Genevant has an opportunity for a highly motivated and skilled Senior/Principal Scientist to join our Pharmaceutical Sciences team. The Senior/Principal Scientist will have a key role in developing formulations and manufacturing processes for mRNA and siRNA lipid nanoparticle (LNP) products in preclinical and clinical stages of development. This position will report to the Director, Pharmaceutical Sciences.
|
|
|
|
Post A Job on the LSBC Website! |
LSBC Membership Discounts on Job Postings
As an LSBC member, your first five job postings EARNS a free repost on BioTalent Canada's The Petri Dish. After your first five reposts, you will also receive 25% off all job postings on The Petri Dish. Want more info? Contact Megan Pan -talent@lifesciencesbc.ca
|
|
|
|
|
|
|
